FDA cleared Tregzi to improve chronic GVHD-free survival, representing a non-pharmacologic strategy to reduce chronic GVHD while supporting immune reconstitution after allogeneic transplantation.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...
Justin Gaethje’s fighting career came full circle under a pair of night skies nearly two decades apart. In 2008, Gaethje had ...
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong ...
Scientists say they have built a cell from scratch for the first time that feeds, grows and replicates like a natural cell, a ...
Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...
Every year, bacteria kill more than a million people worldwide through infections that no longer respond to antibiotics. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results